Eliquis and Benlysta drug interactions - a phase IV clinical study of FDA data

Summary:

Drug interactions are reported among people who take Eliquis (apixaban) and Benlysta (belimumab). Common drug interactions include osteonecrosis among females and gallbladder operation among males.

The phase IV clinical study analyzes what interactions people have when they take Eliquis and Benlysta. It is created by eHealthMe based on reports of 78 people who take the same drugs from the FDA, and is updated regularly.

What is Eliquis?

Eliquis has active ingredients of apixaban. It is often used in atrial fibrillation/flutter. eHealthMe is studying from 191,859 Eliquis users. Check the latest studies of Eliquis.

What is Benlysta?

Benlysta has active ingredients of belimumab. It is often used in systemic lupus erythematosus. eHealthMe is studying from 23,528 Benlysta users. Check the latest studies of Benlysta.



On Jul, 06, 2026

78 people who take Eliquis and Benlysta together, and have interactions are studied.

Eliquis and Benlysta drug interactions.

What are the common drug interactions of Eliquis and Benlysta, by gender? *:

female:

  1. Osteonecrosis (death of bone)
  2. Fall
  3. Gastritis haemorrhagic (inflammation of stomach with bleeding)
  4. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  5. Hyperlipidaemia (presence of excess lipids in the blood)
  6. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)
  7. Leukopenia (less number of white blood cells in blood)
  8. Lymphopenia (an abnormally low level of lymphocytes in the blood)
  9. Pancreatitis acute (sudden inflammation of pancreas)
  10. Peritonitis (inflammation of the peritoneum, the thin tissue that lines the inner wall of the abdomen and covers most of the abdominal organs)

male:

  1. Gallbladder operation

What are the common drug interactions of Eliquis and Benlysta, by age (0-1 to 60+)? *:

0-1:

n/a

2-9:

n/a

10-19:

n/a

20-29:

  1. Dyspnoea (difficult or laboured respiration)
  2. Physical assault

30-39:

  1. Cardiac failure
  2. Pulmonary thrombosis (scarring in the lungs)
  3. Osteonecrosis (death of bone)
  4. Pain
  5. Cardiac failure congestive
  6. Hip arthroplasty
  7. Lymphadenopathy (disease or enlargement of lymph nodes)
  8. Influenza
  9. Drug ineffective

40-49:

  1. Sinusitis (inflammation of sinus)
  2. Poor venous access
  3. Dehydration (dryness resulting from the removal of water)
  4. Malaise (a feeling of general discomfort or uneasiness)
  5. Musculoskeletal disorder (disease of the body's muscles, joints, tendons, ligaments and nerves)
  6. Oxygen consumption increased
  7. Pain
  8. Respiratory syncytial virus infection (viral disease of respiratory system)
  9. Upper respiratory tract infection

50-59:

  1. Hypertension (high blood pressure)
  2. Urticaria (rash of round, red welts on the skin that itch intensely)
  3. Antiphospholipid syndrome (disorder that manifests clinically as recurrent venous or arterial thrombosis and/or fetal loss)
  4. Anxiety disorder
  5. Colitis ulcerative (inflammation of colon with ulcer)
  6. Complex regional pain syndrome (long lasting pain condition most often affecting one of the limbs (arms, legs, hands, or feet))
  7. Coombs positive haemolytic anaemia
  8. Depression
  9. Drug hypersensitivity
  10. Erysipelas (bacterial skin infection)

60+:

  1. Antiphospholipid syndrome (disorder that manifests clinically as recurrent venous or arterial thrombosis and/or fetal loss)
  2. Anxiety disorder
  3. Erysipelas (bacterial skin infection)
  4. Fall
  5. Feeling drunk
  6. Gastritis haemorrhagic (inflammation of stomach with bleeding)
  7. Gastrooesophageal reflux disease (stomach contents (food or liquid) leak backwards from the stomach into the oesophagus)
  8. Hyperlipidaemia (presence of excess lipids in the blood)
  9. Hypertension (high blood pressure)
  10. Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development)

What are the existing conditions these people have? *

  1. White Blood Cell Count Decreased: 27 people, 34.62%
  2. Pain: 17 people, 21.79%
  3. Lymphopenia (an abnormally low level of lymphocytes in the blood): 17 people, 21.79%
  4. Immunodeficiency Common Variable: 6 people, 7.69%

* Approximation only. Some reports may have incomplete information.

Do you take Eliquis and Benlysta?

- Personalize this study to your gender, age, symptoms and drugs
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously



Related studies:

Effectiveness of, side effects of, and alternative drugs to the 2 drugs:

Browse all drug interactions of Eliquis and Benlysta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Sub-studies by gender and age:

Female: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Male: 0-1 2-9 10-19 20-29 30-39 40-49 50-59 60+

Browse all side effects of Eliquis:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all side effects of Benlysta:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Eliquis and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all interactions between Benlysta and drugs from A to Z:

a b c d e f g h i j k l m n o p q r s t u v w x y z

How the study uses the data?

The study uses data from the FDA. It is based on apixaban and belimumab (the active ingredients of Eliquis and Benlysta, respectively), and Eliquis and Benlysta (the brand names). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.



Recent studies on eHealthMe: